Long-term safety of budesonide/formoterol for the treatment of elderly patients with bronchial asthma

  • Authors:
    • Katsunori Kagohashi
    • Hiroaki Satoh
    • Gen Ohara
    • Kunihiko Miyazaki
    • Mio Kawaguchi
    • Koichi Kurishima
    • Nobuyuki Hizawa
  • View Affiliations

  • Published online on: January 30, 2014     https://doi.org/10.3892/etm.2014.1515
  • Pages: 1005-1009
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The long-term safety of budesonide/formoterol (BUD/FM) inhalation has not been fully evaluated, particularly in elderly patients with bronchial asthma. To evaluate the 12-month safety of BUD/FM inhalation for elderly asthmatic patients, the changes in serum potassium levels and pulse rate were examined. A retrospective chart review was conducted of consecutive patients who were treated with BUD/FM inhalation (two inhalations of 160/4.5 mg, twice daily; Symbicort Turbuhaler, AstraZeneca) at a hospital between February 2010 and January 2012. A total of 350 patients were treated with BUD/FM inhalation during the study period and were followed up over 12 months. The mean age of the patients was 60 years, and 19.4% and 21.4% of the patients were aged 65-74 years and ≥75 years, respectively. One hundred and fourteen (32.6%) of the 350 patients continued the inhalation therapy for >12 months. Compared with the pretreatment data, reductions in serum potassium levels at 1, 6 and 12 months were not observed, even in the patients aged 65-74 and ≥75 years. There was also no increase in the pulse rate at 1, 6 and 12 months, even in the patients aged 65-74 and ≥75 years. The usual dosage of BUD/FM showed no adverse effects on the serum potassium levels and pulse rate in the adults, including the elderly with persistent asthma.
View Figures
View References

Related Articles

Journal Cover

2014-April
Volume 7 Issue 4

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kagohashi K, Satoh H, Ohara G, Miyazaki K, Kawaguchi M, Kurishima K and Hizawa N: Long-term safety of budesonide/formoterol for the treatment of elderly patients with bronchial asthma. Exp Ther Med 7: 1005-1009, 2014.
APA
Kagohashi, K., Satoh, H., Ohara, G., Miyazaki, K., Kawaguchi, M., Kurishima, K., & Hizawa, N. (2014). Long-term safety of budesonide/formoterol for the treatment of elderly patients with bronchial asthma. Experimental and Therapeutic Medicine, 7, 1005-1009. https://doi.org/10.3892/etm.2014.1515
MLA
Kagohashi, K., Satoh, H., Ohara, G., Miyazaki, K., Kawaguchi, M., Kurishima, K., Hizawa, N."Long-term safety of budesonide/formoterol for the treatment of elderly patients with bronchial asthma". Experimental and Therapeutic Medicine 7.4 (2014): 1005-1009.
Chicago
Kagohashi, K., Satoh, H., Ohara, G., Miyazaki, K., Kawaguchi, M., Kurishima, K., Hizawa, N."Long-term safety of budesonide/formoterol for the treatment of elderly patients with bronchial asthma". Experimental and Therapeutic Medicine 7, no. 4 (2014): 1005-1009. https://doi.org/10.3892/etm.2014.1515